ReviewNature reviews. Disease primers2020
Pyoderma gangrenosum.
Review in Nature reviews. Disease primers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05120726 (A Novel Therapeutic Treatment of Pyoderma Gangrenosum), which is not on this map. Cited by 135 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Novel Therapeutic Treatment of Pyoderma Gangrenosum
Who cites it
135 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Human Inborn Errors of Immunity in Pyoderma Gangrenosum: A Systematic Review.American journal of clinical dermatology · 2024Pooled it
- Guselkumab as a therapeutic option for recalcitrant pyoderma gangrenosum and Crohn disease: a case report and review of the literature.Skin health and disease · 2026Article
- Selective IL-23 Inhibition in Conventional Treatment-Refractory Pyoderma Gangrenosum: A Multicenter, Retrospective Study.International journal of dermatology · 2026Article
- A progressive nonhealing ulcer on the mandible.JAAD case reports · 2026Article
- Dual-Site Postsurgical Pyoderma Gangrenosum of the Breast and Back With Delayed Diagnosis: A Case Report.The American journal of case reports · 2026Article
- Probable paradoxical pyoderma gangrenosum associated with secukinumab in a patient with severe plaque psoriasis.JAAD case reports · 2026Article
- Pyoderma gangrenosum caused by the molecular uncoupling of OTULIN catalytic activity and LUBAC binding.Nature immunology · 2026Article
- Systemic associations of pyoderma gangrenosum: a systematic review.Skin health and disease · 2026Review
- Pyoderma Gangrenosum Presenting As Recurrent Vulvar Ulceration in a Nine-Year-Old Girl: A Case Report.Cureus · 2026Article
- Article
- A rare case of PAPASH syndrome with a NOD2 mutation.JAAD case reports · 2026Article
- Pyoderma gangrenosum following treatment with azacitidine in a patient with myelodysplastic syndrome.JAAD case reports · 2026Article
- Persistent peristomal pain due to an exposed cutaneous nerve.JAAD case reports · 2026Article
- Pyoderma gangrenosum presenting with pulmonary manifestations.JAAD case reports · 2026Article
- Role of T Helper 2 Signaling in the Regulation of Neutrophil Extracellular Trap Formation in Pyoderma Gangrenosum.The Journal of investigative dermatology · 2026Article
- Concurrent Presentation of Nocardia abscessus Infection and Pyoderma Gangrenosum Following Trauma.Cureus · 2026Article
- A febrile papulovesicular rash in a patient with pyoderma gangrenosum.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- Cutaneous Tuberculosis in the Modern Era: A Case of Lupus Vulgaris with Surgical Management and a Review of Clinical Spectrum, Diagnostic Challenges, and Malignant Potential.Journal of clinical medicine · 2026Article
- Diverging Global Patterns and Temporal Trends in Inflammatory and Infectious Skin Diseases.Clinical, cosmetic and investigational dermatology · 2026Article
- Ulcerative pyoderma gangrenosum in a 78-year-old woman treated with brodalumab: A case report.SAGE open medical case reports · 2026Article
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that presents with rapidly developing, painful skin ulcers hallmarked by undermined borders and peripheral erythema. Epidemiological studies indicate that the average age of PG onset is in the mid-40s, with an incidence of a few cases per million person-years. PG is often associated with a variety of other immune-mediated diseases, most commonly inflammatory bowel disease and rheumatoid arthritis. The cause of PG is not well understood, but PG is generally considered an autoinflammatory disorder. Studies have focused on the role of T cells, especially at the wound margin; these cells may support the destructive autoinflammatory response by the innate immune system. PG is difficult to diagnose as several differential diagnoses are possible; in addition to clinical examination, laboratory tests of biopsied wound tissue are required for an accurate diagnosis, and new validated diagnostic criteria will facilitate the process. Treatment of PG typically starts with fast-acting immunosuppressive drugs (corticosteroids and/or cyclosporine) to reduce inflammation followed by the addition of more slowly acting immunosuppressive drugs with superior adverse event profiles, including biologics (in particular, anti-tumour necrosis factor (TNF) agents). Appropriate wound care is also essential. Future research should focus on PG-specific outcome measures and PG quality-of-life studies.
Indexed as
Identifiers
33033263What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.